Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$23.54 USD

23.54
12,327,695

+1.04 (4.62%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $23.53 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

3 Reasons Why You Should Invest in Baxter International Now

by Zacks Equity Research

Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.

    Zacks Equity Research

    Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View

    by Zacks Equity Research

    Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.

      Zacks Equity Research

      Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates

      by Zacks Equity Research

      Baxter (BAX) gains from strong domestic and international sales in Q1. A raised guidance buoys optimism.

        Zacks Equity Research

        Medical Product Stock Earnings Roster for Apr 26: BAX & More

        by Zacks Equity Research

        Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.

          Zacks Equity Research

          Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?

          by Zacks Equity Research

          IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.

            Zacks Equity Research

            Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?

            by Zacks Equity Research

            A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.

              Zacks Equity Research

              Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

              by Zacks Equity Research

              Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

                Zacks Equity Research

                Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

                by Zacks Equity Research

                Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics

                  Tirthankar Chakraborty headshot

                  4 Top Stocks to Buy With Superb Efficiency Level

                  by Tirthankar Chakraborty

                  Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance

                    Zacks Equity Research

                    Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts

                    by Zacks Equity Research

                    Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.

                      Zacks Equity Research

                      Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK

                      by Zacks Equity Research

                      Baxter (BAX) steadily focuses on improving its Advanced Surgery business.

                        Zacks Equity Research

                        Here's Why You Should Invest in Baxter International Now

                        by Zacks Equity Research

                        Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).

                          Zacks Equity Research

                          Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

                          by Zacks Equity Research

                          Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.

                            Zacks Equity Research

                            Baxter (BAX) Beats on Q4 Earnings and Revenue Estimates

                            by Zacks Equity Research

                            Baxter International Inc. (BAX) reports solid Q4 performance on the back of strong segmental growth.

                              Zacks Equity Research

                              Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More

                              by Zacks Equity Research

                              As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.

                                Zacks Equity Research

                                Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

                                by Zacks Equity Research

                                Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

                                  Zacks Equity Research

                                  Key Factors to Influence PerkinElmer's (PKI) Q4 Earnings

                                  by Zacks Equity Research

                                  PerkinElmer (PKI) solid product portfolio, positive market trends and acquisition are likely to drive earnings in the fourth quarter.

                                    Zacks Equity Research

                                    Baxter (BAX) Launches Arisure Closed System Transfer Device

                                    by Zacks Equity Research

                                    Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.

                                      Zacks Equity Research

                                      Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter

                                      by Zacks Equity Research

                                      Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.

                                        Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: Wal-Mart, Citigroup, Qualcomm, Sherwin-Williams and Baxter

                                        by Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: Wal-Mart, Citigroup, Qualcomm, Sherwin-Williams and Baxter

                                          Zacks Equity Research

                                          Product Innovation Drives Illumina, Downbeat Margins a Woe

                                          by Zacks Equity Research

                                          Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.

                                            Zacks Equity Research

                                            PRA Health (PRAH) Hits 52-Week High on Multiple Positives

                                            by Zacks Equity Research

                                            PRA Health (PRAH) touches 52-week high on consistent revenue performance and Symphony Health integration.

                                              Zacks Equity Research

                                              Zimmer Biomet Suffers a Dull Knee Business & Supply Delay

                                              by Zacks Equity Research

                                              Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.

                                                Zacks Equity Research

                                                Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                                by Zacks Equity Research

                                                Zacks.com highlights: Lululemon Athletica, Chemed, Baxter International, NVR and Copart

                                                  Tirthankar Chakraborty headshot

                                                  5 of the Best Efficient Stocks to Strengthen Your Portfolio

                                                  by Tirthankar Chakraborty

                                                  We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns